Physician profile
Marisa Conti
NPI 1093717621
$3,406.01
in general payments reported to CMS, 2019-2025
28 companies · $308 in 2025
The $308 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $700 · 2020: $391 · 2021: $523 · 2022: $276 · 2023: $544 · 2024: $663 · 2025: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,515.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $744.85 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $481.74 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Glaxosmithkline, LLC. | $244.80 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $211.32 | 2019-2024 | |
| Astellas Pharma US INC | $201.81 | 2019-2023 | Veozah |
| Astrazeneca Pharmaceuticals LP | $199.45 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $152.60 | 2019-2022 | |
| Sanofi Pasteur INC. | $138.97 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $135.14 | 2019-2024 | Capvaxive, Gardasil 9, Gardasil |
| Genentech USA, INC. | $121.97 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $121.30 | 2019-2021 | |
| Amgen INC. | $96.13 | 2019-2025 | Repatha, Evenity, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.87 | 2020-2025 | Jardiance |
| Exact Sciences Corporation | $78.41 | 2023-2024 | Cologuard Collection Kit |
| Dexcom, INC. | $67.38 | 2023-2025 | Dexcom G6 Transmitter |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $59.34 | 2019-2022 | |
| Abbvie INC. | $52.07 | 2021-2024 | |
| Abbott Laboratories | $36.17 | 2021-2023 | Proclaim |
| Sanofi-Aventis U.S. LLC | $32.83 | 2019-2022 | |
| Eisai INC. | $23.31 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.18 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.83 | 2021 | |
| Allergan, INC. | $16.29 | 2020 | |
| Xeris Pharmaceuticals, INC. | $15.96 | 2023 | Gvoke Hypopen |
| Medtronic USA, INC. | $15.70 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.65 | 2022 | |
| Tactile Systems Technology INC | $15.43 | 2024 | Entre Plus, Flexitouch Plus |
| Otsuka America Pharmaceutical, INC. | $13.51 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marisa Conti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.